KRAS features a P-loop containing residues G12 and G13, which are typically mutated in cancers, and has two highly dynamic Switch I and II regions that control substrate and inhibitor binding, respectively (Ostrem et al., 2013 ▸). Here, KRAS is linked to cancer.